Drug intelligence / Profile preview

Bacillus subtilis YHX001J

Development stage
Preclinical
Modality
Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Bacillus subtilis YHX001J is a specific strain of *Bacillus subtilis*, a Gram-positive, catalase-positive bacterium commonly found in soil and the gastrointestinal tracts of humans and animals. While specific details regarding the YHX001J strain are not widely available in public literature, *Bacillus subtilis* in general is recognized as a probiotic with various beneficial effects. Its mechanism of action involves producing antimicrobial substances (such as bacitracin, surfactin, iturin, and fengycin) that inhibit pathogenic bacteria and fungi, competing with pathogens for nutrients and space (competitive exclusion), and normalizing intestinal flora. It also enhances gut microbiota by producing enzymes that improve digestion and nutrient absorption, stimulates immune responses by promoting antimicrobial peptides and gut barrier integrity, and can reduce inflammation. *Bacillus subtilis* is generally recognized as safe (GRAS) by regulatory bodies like the FDA and EFSA, making it an attractive probiotic for various clinical conditions and applications in human and animal health.

Beyond the preview

Go deeper on Bacillus subtilis YHX001J.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacillus subtilis YHX001J.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call